Trial Profile

A Multisite Phase Ib Study of Pevonedistat, Azacitidine (or Decitabine), and Venetoclax (PAVE) for the Treatment of Patients With Acute Myelogenous Leukemia (AML)

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 11 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Pevonedistat (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions
Acronyms PAVE

Most Recent Events

31 May 2024 Status changed from completed to discontinued. (Reason the study was stopped: Takeda P3001 study didn't meet primary endpoint of improvement in event-free survival. There is no regulatory path forward for pevonedistat.)
22 May 2024 Status changed from active, no longer recruiting to completed.
08 Feb 2024 Planned End Date changed from 1 Dec 2025 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com